| Novartis Pharma Schweiz AG - Cosentyx 150 mg / 1 ml, Injektionslösung in einer Fertigspritze |
| 65225 | | 01 | | Cosentyx 150 mg / 1 ml | | Injektionslösung in einer Fertigspritze | | L04AC10 | | Secukinumab | | 20.02.2015 | | |
|
| Composition |
| secukinumabum 150 mg, trehalosum dihydricum, histidinum, histidini hydrochloridum monohydricum, methioninum, polysorbatum 80, aqua ad iniectabile q.s. ad solutionem pro 1 ml. |
| Packungsbestandteile |
| Solution injectable en seringue prête à l'emploi | | | | | | | | Principe actif | Concentr. |
|---|
| Secukinumabum | 150 mg/ml |
| | BAG: Principe actif | Concentr. |
|---|
| Secukinumabum | 150 mg |
| | | | Agents auxilliaires |
|---|
| Histidin Hydrochloride Monohydrate | | Histidine | | Methionine | | Polysorbatum 80 | | Trehalosum Dihydricum |
| |
|
|
